• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?

作者信息

Thyssen J P

机构信息

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

出版信息

Br J Dermatol. 2018 May;178(5):1220. doi: 10.1111/bjd.16330. Epub 2018 Mar 2.

DOI:10.1111/bjd.16330
PMID:29333603
Abstract
摘要

相似文献

1
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?接受度普利尤单抗治疗的特应性皮炎患者发生的结膜炎是否可能由蠕形螨定植和白细胞介素-17水平升高引起？
Br J Dermatol. 2018 May;178(5):1220. doi: 10.1111/bjd.16330. Epub 2018 Mar 2.
2
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors.接受度普利尤单抗治疗的特应性皮炎患者发生的结膜炎是否可能由蠕形螨定植和白细胞介素-17水平升高引起？作者的回复
Br J Dermatol. 2018 May;178(5):1220-1221. doi: 10.1111/bjd.16348. Epub 2018 Mar 2.
3
Cyclosporine 0.1% (Ikervis) treatment in steroid-dependent dupilumab-associated conjunctivitis.0.1%环孢素（Ikervis）治疗依赖类固醇的度普利尤单抗相关结膜炎。
Arch Soc Esp Oftalmol (Engl Ed). 2019 Aug;94(8):396-399. doi: 10.1016/j.oftal.2019.04.013. Epub 2019 Jun 6.
4
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
5
After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?度普利尤单抗获批用于治疗中度至重度特应性皮炎后：研究议程的下一步是什么？
Br J Dermatol. 2018 May;178(5):992-993. doi: 10.1111/bjd.16505.
6
Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.成人中重度特应性皮炎患者使用度普利尤单抗的不良反应：一项荟萃分析。
Int Immunopharmacol. 2018 Jan;54:303-310. doi: 10.1016/j.intimp.2017.11.031. Epub 2017 Nov 25.
7
Diagnosis and Management of Conjunctivitis for the Dermatologist.皮肤科医生的结膜炎诊断与治疗。
J Cutan Med Surg. 2018 Mar/Apr;22(2):200-206. doi: 10.1177/1203475417743233. Epub 2017 Dec 1.
8
Management of dupilumab-associated conjunctivitis in atopic dermatitis.特应性皮炎患者度普利尤单抗相关结膜炎的管理。
J Dtsch Dermatol Ges. 2019 May;17(5):488-491. doi: 10.1111/ddg.13809. Epub 2019 Mar 15.
9
Dupilumab for treatment of atopic dermatitis.度普利尤单抗治疗特应性皮炎。
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.
10
Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.重度特应性皮炎患者接受度普利尤单抗治疗期间的眼部并发症。
Acta Derm Venereol. 2019 Apr 1;99(4):375-378. doi: 10.2340/00015555-3121.

引用本文的文献

1
High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab.接受度普利尤单抗治疗的特应性皮炎患者中睫毛皱襞的高患病率
Acta Derm Venereol. 2025 Aug 18;105:adv43322. doi: 10.2340/actadv.v105.43322.
2
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎：一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
3
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.
曲罗芦单抗有效性和安全性的真实世界证据：一项系统评价与荟萃分析
Am J Clin Dermatol. 2025 May;26(3):411-424. doi: 10.1007/s40257-025-00927-x. Epub 2025 Mar 5.
4
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.度普利尤单抗相关的头颈部皮炎表现出由寡克隆扩增的 T 细胞介导的显著 22 型免疫特征。
Nat Commun. 2024 Apr 2;15(1):2839. doi: 10.1038/s41467-024-46540-0.
5
A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients.一项关于在使用度普利尤单抗的患者中实际应用曲罗芦单抗的回顾性多中心病例系列研究。
JAAD Case Rep. 2024 Feb 1;46:40-44. doi: 10.1016/j.jdcr.2024.01.021. eCollection 2024 Apr.
6
Observation of the clinical features of dupilumab-associated facial erythema.度普利尤单抗相关面部红斑的临床特征观察
Postepy Dermatol Alergol. 2023 Dec;40(6):741-746. doi: 10.5114/ada.2023.132260. Epub 2024 Jan 8.
7
Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions.特应性皮炎和眼部过敏：共同的机制和不常见的问题。
Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):383-389. doi: 10.1097/ACI.0000000000000931. Epub 2023 Jul 28.
8
Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase.利用世界卫生组织药物不良反应数据库对度普利尤单抗相关眼部药物不良反应进行分析。
Adv Ther. 2023 Sep;40(9):3830-3856. doi: 10.1007/s12325-023-02573-3. Epub 2023 Jun 26.
9
Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation.皮肤炎症诱发实验性结膜炎中 IL-4 受体阻断的细胞机制和作用。
JCI Insight. 2023 Feb 8;8(3):e163495. doi: 10.1172/jci.insight.163495.
10
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.度普利尤单抗相关的眼表疾病：澳大利亚环境下处方者的跨学科决策框架。
Australas J Dermatol. 2022 Nov;63(4):421-436. doi: 10.1111/ajd.13924. Epub 2022 Sep 20.